Proteins and Peptides

07 Mar 2017 Revance Completes Enrollment in Phase 3 Pivotal Trials of RT002 Injectable for the Treatment of Glabellar (Frown) Lines
04 Mar 2017 Amgen Presents Overall Survival Data From KYPROLIS® (carfilzomib) Phase 3 ENDEAVOR Trial At 16th International Myeloma Workshop
04 Mar 2017 FDA approves first treatment for frequent urination at night due to overproduction of urine
03 Mar 2017 BIOCAD: The first ever biosimilar of interferon beta-1a approved in Russia
02 Mar 2017 Aurinia Announces Voclosporin Meets 48-Week Remission Endpoints, Achieving Highest Complete Remission Rate of Any Global Lupus Nephritis Study
01 Mar 2017 Phase 3 Head-to-Head Trial Showed KYPROLIS® (Carfilzomib) Significantly Improved Overall Survival Compared To Velcade® (Bortezomib) In Relapsed Or Refractory Multiple Myeloma Patients
01 Mar 2017 Recombinant clotting factor VIII with the name Vihuma® approved
28 Feb 2017 RegeneRx Licensee Receives FDA Permission to Conduct a Phase 3 Trial of RGN-137 for Epidermolysis Bullosa in U.S.
28 Feb 2017 La Jolla Pharmaceutical Company Announces Positive Top-Line Results from ATHOS-3 Phase 3 Study of LJPC-501
21 Feb 2017 CohBar, Inc. Announces Positive Results from Preclinical NASH Study of its Lead Drug Candidates
20 Feb 2017 AstraZeneca enters agreement with TerSera Therapeutics for Zoladex in the US and Canada
20 Feb 2017 Clinical Data from Phase 1 Dose-Escalation Study of Single-Agent NKTR-214 in Patients with Renal Cell Carcinoma Presented at the ASCO 2017 Genitourinary Cancers Symposium
17 Feb 2017 Ascendis Pharma A/S Announces Publication of Comprehensive Results from Randomized, Active-Controlled Phase 2 Trial of Once-Weekly TransCon Growth Hormone in Pediatric Patients
17 Feb 2017 Capricor Therapeutics Provides Update on Natriuretic Peptide Program
16 Feb 2017 U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Pegfilgrastim for Review
16 Feb 2017 Dauntless Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Octreotide Formulation for Intranasal Delivery
16 Feb 2017 Amicus Therapeutics Presents Additional Positive Preliminary Phase 1/2 Data at WORLDSymposium™ 2017
08 Feb 2017 Patient recruitment completed for phase II trial with glepaglutide for treatment of short bowel syndrome
08 Feb 2017 FDA Approves Amgen's Parsabiv™ (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis
06 Feb 2017 Spyryx Biosciences Announces Successful Completion of Phase 1 Clinical Trial for SPX-101 and Planned Phase 2 Initiation in Cystic Fibrosis During 2017
05 Feb 2017 Intarcia Announces FDA Filing Acceptance of New Drug Application (NDA) for ITCA 650 for the Treatment of Type 2 Diabetes
01 Feb 2017 Catalyst Biosciences Announces Positive Preclinical Data of Subcutaneously Dosed Coagulation Factors VIIa and IX at EAHAD Annual Congress
31 Jan 2017 Aeterna Zentaris Announces Completion of Zoptrex™ Pivotal Phase 3 Clinical Trial in Advanced Endometrial Cancer; Expects to Report Top-Line Results in April 2017
27 Jan 2017 Foresee Pharmaceuticals Announces Top-Line Results from Phase 3 Registration Study in Advanced Prostate Cancer
21 Jan 2017 ARMO BioSciences Presents New Phase 1b Clinical Data for AM0010 in Advanced Pancreatic Cancer Patients at 2017 Gastrointestinal Cancers Symposium

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top